


FLAV4AMR: Flavodoxin for Antimicrobial Resistance

“Edificio I+D”, BIFI Institute

9:30	GATHERING OF PARTNERS	Hall
10:00	OPENING AND PRESENTATION	Conference Room
	<p>Enrique Navarro Rodríguez, Director General of Research and Innovation, Gobierno de Aragón</p> <p>Miguel Menéndez, Secretariat Director of the European Projects Office, UZ</p> <p>Javier Sancho, FLAV4AMR coordinator</p>	
10:30	PRESS CONFERENCE	Hall
	<p>Enrique Navarro Rodríguez, Director General of Research and Innovation, Gobierno de Aragón</p> <p>Miguel Menéndez, Secretariat Director of the European Projects Office, University of Zaragoza</p> <p>Javier Sancho, FLAV4AMR coordinator</p> <p>José A. Aínsa, FLAV4AMR partner</p> <p>Ulrich E. Schaible, FLAV4AMR partner</p>	
11:00	C O F F E E B R E A K	“Sala Multiusos”
12:00	ORGANIZATION SESSION	Seminar B room
	All FLAV4AMR partners	
13:00	L U N C H	“Sala Multiusos”
14:30	SCIENTIFIC SESSION	Seminar B room
14:30	Ulrich E Schaible , Research Center Borstel	
15:00	Anke Bollen and Dominik Schwudke , Research Center Borstel First results for setting up an analytical platform for Hp flavodoxin inhibitors by high resolution-mass spectrometry	
15:30	Eliette Touati , Institut Pasteur Analysis of antibacterial effects of Flavodoxin inhibitors in the mouse model of Helicobacter pylori infection	
16:00	José A. Aínsa , BIFI University of Zaragoza	
16:30	Alain Bousquet-Melou , École Nationale Vétérinaire de Toulouse	
17:00	Javier Sancho , BIFI University of Zaragoza Flavodoxin inhibitors. The story and the present	
17:30	SUMMARY SESSION	Seminar B room
	All partners	
18:00	CLOSSING	Seminar B room
18:30	Cultural visit	Palacio de la Aljafería
20:30	D I N N E R	



“Edificio I+D”, BIFI Institute

8:50	WELCOME	Conference Room
	Marta de Miguel Esponera . Chief Executive. Campus Iberus Javier Sancho . FLAV4AMR and INFECMOL coordinator	
	SESSION 1	Conference Room
9:00	<i>Alternative approaches against antimicrobial resistance in tuberculosis.</i> Ulrich E Schaible , Research Center Borstel	
9:30	<i>Lipid metabolism and infection.</i> Dominik Schwudke , Research Center Borstel	
10:00	<i>Helicobacter pylori, oncogenic properties and role in gastric carcinogenesis.</i> Eliette Touati , Institut Pasteur	
10:30	<i>Gastrointestinal diseases and microbiome: A clinical perspective.</i> Ángel Lanas , Digestive Service in Hospital Clínico Universitario Lozano Blesa, Zaragoza, IIS Aragón and University of Zaragoza	
11:00	C O F F E E B R E A K	“Sala Multiusos”
	SESSION 2	Conference Room
11:30	<i>Antituberculosis activity of bacteriocin AS-48.</i> Jose A. Aínsa . BIFI. University of Zaragoza	
12:00	<i>Noncontiguous operon: a new strategy to coordinate bacterial gene expression and its impact during infection.</i> Íñigo Lasa , Navarrabiomed	
12:30	<i>Discovery of Bioactive compounds for PD, PKU and Hp infection. Role of the public Research and Health System in drug discovery.</i> Javier Sancho , BIFI Institute, University of Zaragoza	
13:00	<i>Why are failing to have new antimicrobials despite it’s a great need.</i> José Ramón Paño , Infectious Diseases Service in Hospital Clínico Universitario Lozano Blesa , Zaragoza	
13:30	L U N C H	“Sala Multiusos”
	SESSION 3	Conference Room
15:00	<i>The Hollow Fiber Infection Model. A pre-clinical tool to support anti-infectious drugs development.</i> Alain Bousquet-Melou , École Nationale Vétérinaire de Toulouse	
15:30	<i>Multicenter-study on methicillin-resistant S. aureus CC398 in Spanish hospitals. Antimicrobial resistance and host-adaptive markers and pig-density relationship.</i> Carmen Torres , University of La Rioja	
16:00	<i>Development of new biological screening tests for antibiotic residues detection in foods and live animals.</i> Rafael Pagán , IA2 Institute, University of Zaragoza.	
16:30	<i>Mechanisms of microbial resistance to essential oils.</i> Diego García , IA2 Institute, University of Zaragoza.	
17:00	CLOSING	